可切除或交界可切除胰腺癌新辅助治疗+手术与直接手术治疗的临床对比

目的 探讨新辅助治疗+手术与直接手术治疗可切除或交界可切除胰腺癌的临床效果。方法研究对象为2016年1月至2018年12月期间在中南大学湘雅医学院附属株洲医院接受手术治疗的胰腺癌患者(n=60)，通过术后展开随访调查，回顾性分析直接手术治疗(直接手术组，n=30)与新辅助治疗+手术治(联合治疗组，n=30)患者的临床疗效。结果 联合治疗组相较于直接手术组患者其术后生存率明显提高(χ²=3.880,P=0.049)；联合治疗组患者术后1年及3年总体生存率分别为96.67%与80.00%，均较直接手术组的73.33%与53.33%更高，对比均有统计学差异(χ²=6.405,P=0.011；χ²=4.800,P=0.028)；联合治疗组术后胰腺癌复发率及转移率分别为10.00%与43.33%，均较直接手术组的33.33%与70.00%更低，对比均有统计学差异(χ²=4.811,P=0.028；χ²=4.343,P=0.037)；联合治疗组术后并发症发生率为26.67%，较直接手术组的...

Clinical efficacy of neoadjuvant therapy plus surgery treatment versus direct surgery treatment for resectable or borderline resectable pancreatic cancer

Objective To investigate and compare the clinical efficacy of neoadjuvant therapy plus surgery treatment versus direct surgery treatment for resectable or borderline resectable pancreatic cancer. Methods The research subjects were pancreatic cancer patients (n=60) who received surgical treatment in Zhuzhou Hospital between Jan. 2016 and Dec. 2018. By postoperative follow-up survey, the clinical efficacy of patients in the direct surgery treatment group (n=30) and the combined treatment group (neoadjuvant therapy plus surgery treatment,n=30) were retrospectively analyzed. Results Compared with those in the direct surgery treatment group, the survival rate of patients in the combined treatment group was significantly improved (χ² =3.880, P=0.049). The 1- and 3-year survival rates in the combined treatment group were 96.67% and 80.00%, respectively, which were significantly higher than those in the direct surgery treatment group (73.33% and 53.33%, respectively,χ² =6.405, P=0.011; χ² =4.800, P=0.028). Postoperative recurrence and metastasis rate of pancreatic cancer in combined treatment group were 10.00% and 43.33%, respectively, which were significantly lower than those in the direct surgery treatment group (33.33% and 70.00%, respectively, χ² =4.811, P=0.028; χ² =4.343, P=0.037). The incidence of postoperative complications in combined treatment group (26.67%) was slightly lower than that in the direct surgery treatment group (33.3%, χ² =0.317, P=0.573). Conclusion For patients with resectable or borderline resectable pancreatic cancer, neoadjuvant therapy plus surgery is superior in reducing the postoperative recurrence and metastasis rate of pancreatic cancer, while ensuring clinical efficacy and safety, prolonging the survival time and improving the prognosis.